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MicroRNAs (miRNAs) are an evolutionarily conserved class of endogenous, non-coding RNAs that
modulate gene expression at the post-transcriptional level and are involved in tumorigenesis. In this
study, we demonstrate that miR-1 suppresses the potential for growth, migration and invasion in
the HEp2 cell line. Furthermore, we validate that FN1 is a direct target gene for miR-1 via ﬂuorescent
reporter assay and is negatively regulated by miR-1. Moreover, the knockdown of FN1 has the same
phenotypic effects as the overexpression of miR-1. Taken together, our results provide evidence that
miR-1 may play a role as a tumor suppressor gene in laryngeal carcinoma.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
MicroRNAs (miRNAs) are small, non-coding RNAs that nega-
tively regulate mRNA translation or stability [1] by interacting with
the 30 UTRs of their target gene mRNAs. The 30 UTRs of mRNAs con-
tain key stability elements that are subject to various regulatory
proteins and are also miRNA binding sites [2]. The miRNAs play
critical roles in myriad processes, including cell fate, cellular differ-
entiation, cancer, apoptosis, metabolism, immunity and develop-
ment stress responses [3–5].
Aberrations in the expression of miRNA are associated with dis-
eases, such as neuronal disorders [6], inﬂammation [7] and cancer
[8]. Tumor-related miRNA expression has been identiﬁed by proﬁl-
ing, and distinct miRNA signatures for many types of cancers,
including laryngeal carcinoma, have been reported [9–11]. Fur-
thermore, depending upon the cell type, several miRNAs that arechemical Societies. Published by E
DNA, complementary DNA;
N1, ﬁbronectin1; GAPDH,
seradish peroxidase; miR-1,
ylthiazol-2-yl)-2,5-diphenyl-
R, untranslated regionderegulated in human malignancies exhibit oncogenic or tumor
suppressor properties [8]. For example, let-7a and miR-34c are
downregulated in laryngeal carcinoma and function as tumor sup-
pressors [11,12], whereas miR-21 functions as an oncogene [13].
Thus, miRNAs play critical roles in tumorigenesis and may poten-
tially serve as biomarkers and targets for anticancer therapy.
One of the most evolutionarily conserved miRNAs is miR-1,
which is highly enriched in heart and muscle where it plays impor-
tant roles in the proliferation of progenitor cells and myogenesis
[14,15]. In addition, it has been reported that miR-1 was released
into the blood of Duchenne muscular dystrophy (DMD) patients
as a consequence of muscle degeneration, and the amount of
miR-1 paralleled the severity of the disease [16]. Several other
observations showed that miR-1 is downregulated in the liver can-
cer and functions as a tumor suppressor [17]. These ﬁndings indi-
cate that miR-1 is a molecule with multiple roles. Our previous
study found that miR-1 was downregulated in laryngeal carcinoma
tissues compared to adjacent normal tissues [13]. However, the
function and molecular mechanism of miR-1 in laryngeal carci-
noma cells remains unknown.
In this study, we addressed miR-1 as a negative regulator of
migration and invasion of HEp2 laryngeal carcinoma cells and
identiﬁed ﬁbronectin 1 (FN1) as a miR-1 target gene that mediated
its effect on the cellular phenotype.lsevier B.V. All rights reserved.
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2.1. Cell culture, transfection and isolation of RNAs
The human laryngeal carcinoma cell line HEp2 was maintained
in RPMI1640 (GIBCO BRL, Grand Island, NY, USA) supplemented
with 10% fetal bovine serum (FBS), 100 IU/ml of penicillin and
100 lg/ml of streptomycin. The cell line was incubated at 37 C
in a humidiﬁed chamber supplemented with 5% CO2. Transfection
was performed with Lipofectamine 2000 Reagent (Invitrogen,
Carlsbad, CA, USA) following the manufacturer’s protocol. Total
RNA was extracted from HEp2 cells using TRIzol reagent (Invitro-
gen, CA, USA) according to the manufacturer’s instructions.
2.2. Bioinformatic method
The miRNA targets were predicted using the algorithms Target-
Scan, PicTar, and MiRBase Targets. We used MatchMiner to identify
the genes commonly predicted by the three different algorithms.
2.3. Immunohistochemistry
Five pairs of primary laryngeal squamous carcinoma tissues and
adjacent normal tissues were obtained from the patients in Tianjin
People’s Hospital (Tianjin, China). The detail information of speci-
mens was in the suppl. table S1. The study was approved by the
Institutional Review Board of Tianjin People’s Hospital. Immuno-
histochemistry (IHC) was performed according to the methods
described previously [18]. Being pretreated with microwave, the
sections were blocked and incubated using monoclonal mouse
anti-human FN1 (Tianjin Saierbio, China). Staining intensity was
assessed.
2.4. Statistical analysis
The statistical signiﬁcance of differences between groups was
analyzed by the unpaired Student’s t test, and P 6 0.05 was consid-
ered to be statistically signiﬁcant. One representative experiment
is shown in triplicates in the statistical analysis.
The other materials andmethods are in the Supplementary data.
3. Results
3.1. miR-1 suppresses the growth of HEp2 cells
In a previous study, we found that miR-1 was signiﬁcantly
downregulated in laryngeal carcinoma tissues [13]. In order to
investigate the effect of miR-1 on cellular phenotypes, we ﬁrst
made a miR-1 expression construct, pcDNA3/pri-miR-1, and con-
ﬁrmed its efﬁciency. Real-time PCR showed that miR-1 level was
increased approximately 3.8-fold in HEp2 cells transfected with
pcDNA3/pri-miR-1 compared to the control vector (Fig. 1A). How-
ever, miR-1 level decreased by approximately 70% in HEp2 cells
transfected with miR-1 ASO compared to the control oligomer
(Fig. 1B). The MTT assay was used to evaluate cell viability. The
assay indicated that either ectopic expression of miR-1 or blocking
miR-1 by ASO did not obviously alter HEp2 cell viability at 24 h,
48 h and 72 h post-transfection (Fig. 1C and D). To further deter-
mine the effect of miR-1 on the growth of HEp2 cells, a colony for-
mation assay was performed. The colony formation rate of HEp2
cells transfected with pcDNA3/pri-miR-1 declined by approxi-
mately 75% but increased nearly 3-fold in HEp2 cells transfected
with miR-1 ASO compared to their respective control groups
(Fig. 1F and G). To conﬁrm the effect of miR-1 on HEp2 cell growth,
we synthesized a mutant miR-1 in which six bases were mutated.
The mutant miR-1 did not affect HEp2 cell viability and abolishedthe inﬂuence of miR-1 in the colony formation assay on HEp2 cells
(Fig. 1E and H). These results indicate that miR-1 can promote col-
ony formation in HEp2 cells but does not affect cell viability.
3.2. miR-1 suppresses the properties of migration and invasion of HEp2
cells
Next, to identify the potentials for migration and invasion of
tumor cells that might be relevant to malignancy, in vitro migra-
tion and invasion assays were employed. First, we performed a
migration transwell assay to determine the migratory ability of lar-
yngeal carcinoma cells. As shown in Fig. 2A, 38% of cells over-
expressing miR-1 migrated to the basal side of the membrane
compared to control cells. In contrast, 40% more of HEp2 cells tran-
siently transfected with miR-1 ASO migrated than the negative
control group. Subsequently, we determined invasive properties
by the invasion transwell assay. We found that the average number
of HEp2 cells transfected with pri-miR-1, which invaded the basal
side of the membrane, was 36% fewer than that of the control
group. Alternatively, invasion increased 1.9-fold in cells with
downregulated miR-1 (using miR-1 ASO), as compared to the con-
trol group (Fig. 2B). To conﬁrm this speciﬁc effect of miR-1 on the
migration and invasion of HEp2 cells, migration and invasion
transwell assays were performed with cells transfected with
miR-1-mut and NC-mut. The data from the two groups showed
no differences (Fig. 2C and D). These data show that miR-1 is an
important participant in the reduction of migration and invasion
potential of laryngeal carcinoma cells.
3.3. miR-1 directly targets FN1 and down-regulates its expression
The identiﬁcation of miR-1-regulated targets is a necessary step
in understanding howmiR-1 functions. Target genes of miR-1 were
predicted using three programs, PicTar, TargetScan and miRBase
Targets. Although there were a variety of candidate target genes,
FN1, ANP32B, CCND2, DDX5, E2F5, EIF4E, GAS2L, MAP4K3, MMD2
and SOX6 etc, we chose FN1 as a target gene of miR-1 due to its
tumor migration and invasion associated functions, which were
consistentwith the effects ofmiR-1 on the phenotypes inHEp2 cells.
The alignment of miR-1 with the FN1 mRNA 30 UTR, which carries a
putative miR-1 binding site, is illustrated in Fig. 3A. To determine
whether miR-1 directly regulates FN1, an enhanced green ﬂuores-
cent protein (EGFP) reporter assay was used to validate the target
site in the FN1 30 UTR. The 334-bp 30 UTR region containing the pre-
dicted miR-1 binding site was inserted downstream of the EGFP
gene following a stop codon (pcDNA3/EGFP-FN1-30 UTR). First, we
transfected either pcDAN3/EGFP or pcDNA3/EGFP-FN1-30UTR into
HEp2 cells. We found that cells transfected with pcDNA3/EGFP-
FN1-30UTR had lower EGFP expression, indicating that endogenous
miR-1 had an effect on the FN1 30UTR (Fig. 3B). HEp2 cells were
transfected with the reporter vector, as well as pcDNA3/pri-miR-1
or a control vector and miR-1 ASO or a control sequence, respec-
tively. Interestingly, we found that EGFP expression declined by
48% compared to the control group whenmiR-1 was overexpressed
by transfecting cells with pri-miR-1. Alternatively, suppression of
miR-1 with miR-1 ASO increased EGFP expression 1.35-fold
(Fig. 3C). To further determine the functionof themiR-1binding site,
we constructed another EGFP reporter vector containing the FN1 30
UTRwith four mutatedmiR-1 binding sites (Fig. 3A). As a result, the
observed alteration of EGFP intensity was abolished after transfec-
tion with this vector (Fig. 3B and C). We thus conclude that FN1 is
a direct target gene of miR-1.
To assess whether miR-1 functions in the downregulation of
endogenous FN1 expression, HEp2 cells were transfected with
either pcDNA3/pri-miR-1 or miR-1 ASO to overexpress or block
miR-1, respectively. Expression of FN1 mRNA was then measured
Fig. 1. The growth of HEp2 cells is suppressed in vitro by miR-1. (A, B) The miR-1 expression level in HEp2 cells was effectively altered by transfection of pri-miR-1 or miR-1
ASO, as detected by real-time RT-PCR. U6 snRNA was used for normalization. (C–E) MTT assays were performed to determine the effect of miR-1 on cell vitality. (F–H) Colony
formation assays were employed to detect the effect of miR-1 on the cell growth activity of HEp2 cells. Experiments were performed in triplicate (⁄P < 0.05, ⁄⁄P < 0.01).
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mRNA was diminished by 79% or elevated 5.24-fold, respectively,
compared to the control groups (Fig. 4A and B). In addition, to
determine whether miR-1 effects the expression of the FN1
protein, a western blot was performed. The FN1 protein level
was reduced by approximately 77% in HEp2 cells transfected with
pri-miR-1 (Fig. 4C) and was elevated 3.56-fold after transfection
with miR-1 ASO (Fig. 4D) compared to the respective controls.
Moreover, immunoﬂuorescence assays showed that FN1 expres-
sion was weaker in HEp2 cells treated with pri-miR-1 following
incubation with anti-FN1 compared to controls. However, FN1
expression was stronger in HEp2 cells transfected with miR-1
ASO than in control cells (Fig. 4E). These data show that FN1 is reg-
ulated by miR-1 at the mRNA and protein levels.
3.4. Knockdown of FN1 suppresses cellular growth, migration and
invasion in vitro
Sequence-speciﬁc small interfering RNA (siRNA) can effectively
suppress gene expression. To determine the inﬂuence of FN1 on
the growth, migration and invasion of HEp2 cells, FN1 expression
was knocked down by a FN1 siRNA expression plasmid, pRNAT
U6.2/si-FN1 (pU6.2/si-FN1). Western blot and qRT-PCR analyses
showed that transfection of HEp2 cells effectively suppressedapproximately 79% of FN1 expression on the mRNA level and
52% on the protein level when compared to control groups
(Fig. 5A and B). Next, MTT assays showed that FN1 did not affect
cell vitality. We also explored the capability of cell growth and
mobility (Fig. 5C). Subsequently, colony formation assays were em-
ployed to evaluate the effect of silencing FN1 on the growth of
HEp2 cells. The colony formation rate was lower for cells where
FN1 was knocked down with siRNA than in the control group
(Fig. 5D). Consequently, transwell assays examining migration
and invasion were performed. The average numbers of HEp2 cells
transfected with si-FN1 that were seen to migrate and invade were
fewer than seen with control cells (Fig. 5E and F). These results
indicate that the knockdown of FN1 suppresses cell growth and
mobility in the laryngeal carcinoma cell line HEp2.
3.5. Expression of FN1 in laryngeal squamous carcinoma tissues
To detect the level of FN1 in laryngeal squamous carcinoma tis-
sues, we collected 5 pair of laryngeal squamous carcinoma tissues
and adjacent normal tissues, and performed immunohistochemis-
try staining. As shown in Fig. 6, the expression levels of FN1 were
higher than that in adjacent normal tissues. The result indicates
that miR-1 and FN1 may be negative correlations in laryngeal
squamous carcinoma tissues.
Fig. 2. Effects of miR-1 on the migration and invasion of HEp2 cells. (A, C) Transwell assays without Matrigel were performed to detect the migration activity of HEp2 cells
transfected with pcDNA3/pri-miR-1, miR-1 ASO or miR-1-mut and their respective control sequences. (B, D) Transwell assays with matrigel were used to detect the invasion
activity of HEp2 cells after transfection. Experiments were performed in triplicate (⁄P < 0.05, ⁄⁄P < 0.01).
Fig. 3. The 30 UTR of FN1mRNA is directly targeted by miR-1. (A) The wild type (wt) and mutant complementary sequences of the FN1mRNA 30UTR are shown with the miR-1
sequence. (B, C) EGFP reporter assays were performed to conﬁrm the direct interaction of miR-1 with the FN1 30 UTR. HEp2 cells were transfected with EGFP reporter vector,
as well as the pri-miR-1 or miR-1 ASO, and the relative EGFP intensity was measured. The experiment was performed in triplicate (⁄P < 0.05, #no statistical signiﬁcance).
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Head and neck squamous cell carcinoma (HNSCC) is the sixth
most frequentcancer, and laryngeal squamouscell carcinoma (LSCC)
is themost commonHNSCC[19,20].Althoughconsiderable advanta-
ges are seen with multimodality therapy, the overall ﬁve-yearsurvival rate forpatientswith this typeof cancer is among the lowest
of all major cancer types and has not improved in recent years [21].
Understanding the carcinogenic mechanisms of LSCC may help to
ﬁnd amarker and further develop treatment approaches to improve
the cure and survival rates of this cancer. Recently, an increasing
number of miRNAs are being discovered that are involved in the
Fig. 4. Fibronectin1 (FN1) is negatively regulated by miR-1. A and B: When miR-1 was overexpressed or blocked, the level of FN1 mRNA was subsequently diminished or
elevated, respectively, as compared to the control group. C and D: When miR-1 was overexpressed or blocked, the level of FN1 protein was subsequently diminished
or elevated, respectively, as compared to the level in the control group. E: HEp2 cells were transfected with pri-miR-1 or miR-1 ASO, and FN1 protein expression was reduced
or enhanced, respectively. Experiments were performed in triplicate (⁄P < 0.05, ⁄⁄P < 0.01).
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mulating evidence suggests that miRNAs play important roles in
bothnormal cellular identity and in thepathological state, especially
in tumorigenesis.
Previously, we performed miRNA microarray assays to ﬁnd 13
miRNAs that were differentially expressed between laryngeal car-
cinoma samples and normal laryngeal tissues. We showed that
miR-1 was notably downregulated in cancer tissues compared
with normal tissues [13]. We presumed that the lower expression
level of miR-1 was associated with the malignancy of laryngeal
carcinoma. Therefore, we performed a further investigation of the
effect of miR-1 on the growth and invasion of the human laryngealcarcinoma cell line HEp2. Interestingly, though miR-1 had no sig-
niﬁcant effect on the viability of HEp2 cells (Fig. 1), the impact of
miR-1 on cell growth, migration and invasion is remarkable
(Fig. 2). Mutating miR-1 abolished these effects. We just used
HEp2 cell in this study because no other laryngeal carcinoma cell
line was available. Even though, we detected the effects of miR-1
on the cellular phenotypes in HeLa human cervical cancer cell line
(Suppl. Fig. S1) and QGY-7703 human hepatocellular carcinoma
cell line (Suppl. Fig. S2) (data shown in the Supplementary data)
and got similar results with those in HEp2 cells. Besides the two
tumors, it was reported that miR-1 was downregulated and had
suppressive effects on cell proliferation and mobility in lung cancer
Fig. 5. FN1 promotes cell growth and mobility in HEp2 cells. (A, B) HEp2 cells were transfected with a siRNA targeting FN1, causing the suppression of the mRNA and protein
levels of FN1. (C, D) FN1 expression was knocked down in HEp2 cells, and cell growth activity was detected by MTT and colony formation assays. (E, F) Knockdown of FN1
suppresses the migration and invasion potential of HEp2 cells. Experiments were performed in triplicate (⁄P < 0.05, ⁄⁄P < 0.01).
Fig. 6. The expression level of FN1 in laryngeal squamous carcinoma tissues. The expression of FN1 was detected in laryngeal squamous carcinoma tissues and adjacent
normal tissues by IHC (n = 5).
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may play a tumor suppressor role in several kinds of tumor cells,
including the human laryngeal carcinoma cells.
It has been reported that the aberrant expression of miR-1 con-
tributed to the malignant phenotype through the inhibition of cell
cycle progression and the induction of apoptosis in hepatocellular
carcinoma [17]. Moreover, a reported study implicates miR-1 in
the initial dampening of stress response genes and in governing
sets of genes used during periods of pressure overload. Serum
response factor (SRF) is a direct upstream regulator of both c-Fos
and miR-1, suggesting that SRF activates the transcriptional medi-
ators of the immediate early gene response and, in a negative feed-
back loop, limits the extent of the stress response by activating
miR-1 expression [24]. An additional study demonstrates a func-
tional relationship between EVI1 and miR-1-2/miR-133a-1 cluster
expression in acute myeloid leukemia (AMP) [25]. These ﬁndingsare consistent with our results, showing that miR-1 functions as
a tumor suppressor.
As is commonly known,miRNAs are required to bind to their tar-
get genes in order to regulate gene expression [26]. We used bioin-
formatics to predict that FN1 is a candidate target of miR-1 and
employed an EGFP reporter system, real-time PCR, western blot
analysis and immunoﬂuorescence to conﬁrm that FN1 is a direct
target gene of miR-1. Moreover, miR-1-mediated suppression of
FN1 is dependent on the 30 UTR of the FN1 mRNA. Furthermore,
immunostaning indicates the FN1 is overexpressed in laryngeal
squamous carcinoma tissues compared with adjacent normal
tissues. Although no sufﬁcient samples were available, FN1 was
detected in the laryngeal squamous carcinoma tissues and it had
a negative relationship with miR-1. Because we did not collect
enough samples, it is difﬁcult to tell the relationship between the
clinical stage of laryngeal carcinoma and the expression of miR-1
F. Wang et al. / FEBS Letters 585 (2011) 3263–3269 3269and FN1. Finally, knockdown of FN1 with siRNA represses cell
growth, migration and invasion activity, which is consistent with
ectopic expression of miR-1. Therefore, these results highlight the
signiﬁcance of miR-1 as a tumor suppressor in the malignancy of
laryngeal carcinoma by targeting FN1.
FN1 is an extracellularmatrix glycoprotein that playsmajor roles
in cell differentiation, growth and migration. It is involved in such
processes as wound healing and embryonic development, as well
as oncogenic transformation [27,28]. For instance, ﬁbronectin (FN)
and TG2 facilitate the metastatic activity of A431 tumor cells, and
this mediation may be partly attributed to the enhancement of the
association of FN and b integrin by TG2 [29]. Also, FN is a key medi-
ator of glioma progression through a mechanism that involves the
maintenance of integrin b1 ﬁbronectin receptors in glioma cells.
These receptors are required by ﬁbronectin to induce a Src kinase-
dependent survivin activity, which promotes brain tumor prolifera-
tion [30]. In addition, the expression levels of ﬁbronectin and the
ﬁbronectin type-III domain containing 3A (FNDC3A) protein are
reduced by miR-17 in vitro and in transgenic mice. Also, miR-17
causes cellular defects through its repression of ﬁbronectin expres-
sion [31]. In this study, we found thatmiR-1 can negatively regulate
FN1 by targeting its 30 UTR and suppresses the growth and invasion
of HEp2 human laryngeal carcinoma cells.
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